J-147 — Safety, Research, Risks & Legal Status

Not medical advice. J-147 is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	J147, curcumin/CNB-001-derived CMC compound, CAS 1146963-51-0
Category	Research Chemical
Drug class	Synthetic curcumin-derived neuroprotective/neurotrophic small molecule (CMC compound)
Proposed target	Mitochondrial ATP synthase alpha subunit (ATP5A); AMPK/mTOR signaling
Origin	Salk Institute (Schubert/Maher labs), first reported ~2011
Developer	Abrexa Pharmaceuticals (clinical development)
Highest trial stage	Phase 1 single-ascending-dose safety/PK in healthy volunteers (NCT03838185)
Route / CAS	Oral, brain-penetrant; CAS 1146963-51-0
US legal status	Not FDA-approved and not a lawful dietary supplement. J-147 is an investigational new chemical entity that has only reached an early-stage (Phase 1) human safety study; it carries no approved therapeutic indication. It does not qualify as a dietary ingredient under DSHEA and cannot be lawfully marketed or sold as a supplement in the US. Material found online is typically offered gray-market as a "research chemical, not for human consumption." The compound itself is not specifically scheduled, but selling it for human use would be an unapproved new-drug violation under the FD&C Act. Informational only; Peptropix does not sell J-147.

What is J-147?

J-147 is a synthetic, orally active small molecule developed as an experimental treatment for Alzheimer's disease and brain aging. It was created at the Salk Institute (the labs of David Schubert and Pamela Maher) by structurally optimizing the curry-spice polyphenol curcumin through an intermediate compound, CNB-001, and was first reported around 2011. Unlike anti-amyloid antibody drugs, J-147 was selected in cell-based (phenotypic) screens for broad neuroprotection against age-associated cellular toxicities rather than against a single predefined target. It is a research compound, not a marketed drug or a supplement, and the large majority of the evidence behind it is preclinical.

How it works

The proposed primary molecular target, identified by affinity approaches, is the alpha subunit of mitochondrial ATP synthase (ATP5A). J-147 is reported to partially inhibit ATP synthase activity, which modestly raises the intracellular AMP/ATP ratio and intracellular calcium. This is proposed to activate the CAMKK2 to AMPK signaling axis with downstream modulation of mTOR, a pathway broadly associated with cellular stress resistance, mitochondrial homeostasis, and longevity signaling. Secondary and possibly upstream effects reported in cell models include protection against oxytosis/ferroptosis-type oxidative cell death, reduced neuroinflammation, and increased neurotrophic factor expression. The mechanism is best described as proposed and preclinical; the relative contribution of ATP synthase binding versus broader antioxidant and neurotrophic actions to any behavioral effect is not fully resolved.

Background & history

J-147 emerged from a Salk Institute program (David Schubert, Pamela Maher, and colleagues) that used phenotypic, age-related toxicity screens rather than target-based screening. Starting from curcumin, the team generated the analog CNB-001 and then J-147, first described in the literature around 2011, as an orally bioavailable, brain-penetrant compound with improved potency and stability over curcumin. Over the following decade the group published rodent efficacy and mechanism papers, culminating in the 2018 identification of ATP synthase as a target and reports framing J-147 as both an Alzheimer's candidate and a broader anti-aging (geroprotective) molecule. Development was carried forward commercially by Abrexa Pharmaceuticals, which registered and ran the Phase 1 human safety study beginning around 2019.

What the research says

Efficacy evidence is preclinical and comes largely from a single research lineage. In transgenic APP/PS1 Alzheimer's mice and in aged, rapidly senescing SAMP8 mice, chronic oral J-147 (commonly around 10 mg/kg/day) has been reported to improve memory, reduce soluble amyloid-beta, lower oxidative-stress and inflammatory markers, raise BDNF/NGF, and partially reverse age-associated transcriptomic and metabolic changes. These are animal-model findings, have not been broadly replicated by independent laboratories, and rodent Alzheimer's models translate poorly to humans. Human data are limited to a single Phase 1 study (NCT03838185, sponsored by Abrexa Pharmaceuticals): a randomized, double-blind, placebo-controlled single-ascending-dose safety and pharmacokinetics trial in healthy young and elderly volunteers. That trial was designed to assess tolerability and PK, not efficacy. There are no completed efficacy trials in Alzheimer's patients and no robust human evidence that J-147 improves cognition or alters disease course.

Reported effects

Reported in animals to improve memory and learning in Alzheimer's and aging models (not established in humans)
Preclinical increases in neurotrophic factors BDNF and NGF, supporting synaptic plasticity in rodent studies
Reduction of soluble amyloid-beta and markers of oxidative stress in transgenic mouse brain
Proposed neuroprotection against age-associated toxicities (glutamate/oxytosis, energy stress) in cell models
Anti-inflammatory and metabolic effects reported preclinically, including AMPK-linked changes in liver lipid handling
No verified cognitive or subjective effects have been demonstrated in controlled human trials

Dosing & administration (informational)

Informational only, not a protocol and not medical advice. The dosing figure most often cited is drawn from animal studies, typically around 10 mg/kg/day orally in mice, which cannot be linearly scaled to a human dose. Human exposure has only been studied in a Phase 1 single-ascending-dose safety and pharmacokinetics setting in healthy volunteers, and those doses are not publicly established as an efficacious or approved regimen. There is no validated human dose, no defined therapeutic window, and no approved indication. Any numbers circulating in vendor or forum material should be treated as unverified.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Human safety data are limited to one Phase 1 single-ascending-dose study in healthy volunteers; long-term human safety is unknown
No established safe dose, no chronic-exposure data, and no data in people with existing disease or on other medications
Because it activates AMPK/mTOR-linked and mitochondrial pathways, systemic metabolic and possibly cardiovascular effects cannot be excluded without more data
Gray-market material is unregulated: identity, purity, and dose accuracy are not guaranteed and contamination is a real risk
Not evaluated in pregnancy, breastfeeding, or for developmental safety; assume unsafe in these contexts
Self-experimentation with an investigational drug outside a trial carries unquantified risk and no medical oversight
Any use for a suspected cognitive or neurodegenerative condition should be discussed with a physician rather than self-treated

Drug & supplement interactions

F
o
r
m
a
l
h
u
m
a
n
d
r
u
g
-
i
n
t
e
r
a
c
t
i
o
n
s
t
u
d
i
e
s
h
a
v
e
n
o
t
b
e
e
n
p
u
b
l
i
s
h
e
d
.
M
e
c
h
a
n
i
s
t
i
c
a
l
l
y
,
b
e
c
a
u
s
e
J
-
1
4
7
e
n
g
a
g
e
s
A
M
P
K
/
m
T
O
R
-
l
i
n
k
e
d
a
n
d
m
i
t
o
c
h
o
n
d
r
i
a
l
e
n
e
r
g
y
p
a
t
h
w
a
y
s
,
t
h
e
o
r
e
t
i
c
a
l
a
d
d
i
t
i
v
e
e
f
f
e
c
t
s
w
i
t
h
o
t
h
e
r
a
g
e
n
t
s
a
c
t
i
n
g
o
n
t
h
o
s
e
p
a
t
h
w
a
y
s
(
f
o
r
e
x
a
m
p
l
e
m
e
t
f
o
r
m
i
n
o
r
o
t
h
e
r
A
M
P
K
a
c
t
i
v
a
t
o
r
s
)
c
a
n
n
o
t
b
e
e
x
c
l
u
d
e
d
.
I
t
s
c
u
r
c
u
m
i
n
l
i
n
e
a
g
e
r
a
i
s
e
s
t
h
e
p
o
s
s
i
b
i
l
i
t
y
o
f
e
f
f
e
c
t
s
o
n
d
r
u
g
-
m
e
t
a
b
o
l
i
z
i
n
g
e
n
z
y
m
e
s
a
n
d
o
n
a
n
t
i
p
l
a
t
e
l
e
t
/
a
n
t
i
c
o
a
g
u
l
a
n
t
a
c
t
i
v
i
t
y
,
t
h
o
u
g
h
t
h
i
s
h
a
s
n
o
t
b
e
e
n
c
h
a
r
a
c
t
e
r
i
z
e
d
f
o
r
J
-
1
4
7
s
p
e
c
i
f
i
c
a
l
l
y
.
A
n
y
r
e
a
l
-
w
o
r
l
d
c
o
m
b
i
n
a
t
i
o
n
w
i
t
h
p
r
e
s
c
r
i
p
t
i
o
n
m
e
d
i
c
a
t
i
o
n
s
,
e
s
p
e
c
i
a
l
l
y
i
n
o
l
d
e
r
a
d
u
l
t
s
o
r
p
e
o
p
l
e
w
i
t
h
n
e
u
r
o
d
e
g
e
n
e
r
a
t
i
v
e
d
i
s
e
a
s
e
,
i
s
u
n
s
t
u
d
i
e
d
a
n
d
s
h
o
u
l
d
b
e
r
e
v
i
e
w
e
d
w
i
t
h
a
c
l
i
n
i
c
i
a
n
.

Who should avoid it

Anyone who is pregnant, breastfeeding, or may become pregnant
People taking prescription medications, particularly for diabetes, cardiovascular, or neurological conditions, given unknown interactions
People seeking to treat diagnosed Alzheimer's disease or cognitive decline outside of a supervised clinical trial
Anyone expecting a proven or approved cognitive benefit, since none has been demonstrated in humans
Individuals unwilling or unable to verify identity and purity of gray-market material

How it is commonly combined

There is no evidence-based rationale for stacking J-147 with other compounds, and no human data support any combination. Because it is investigational, its safety and pharmacokinetics are not characterized well enough to predict how it behaves alongside other nootropics, supplements, or drugs. Combining an unapproved research chemical with other actives compounds the uncertainty rather than reducing it. Peptropix does not endorse or describe stacking protocols for J-147.

Legal & regulatory. Not FDA-approved and not a lawful dietary supplement. J-147 is an investigational new chemical entity that has only reached an early-stage (Phase 1) human safety study; it carries no approved therapeutic indication. It does not qualify as a dietary ingredient under DSHEA and cannot be lawfully marketed or sold as a supplement in the US. Material found online is typically offered gray-market as a "research chemical, not for human consumption." The compound itself is not specifically scheduled, but selling it for human use would be an unapproved new-drug violation under the FD&C Act. Informational only; Peptropix does not sell J-147.

Quality & harm reduction

T
h
e
r
e
i
s
n
o
p
h
a
r
m
a
c
e
u
t
i
c
a
l
-
g
r
a
d
e
,
F
D
A
-
r
e
g
u
l
a
t
e
d
s
o
u
r
c
e
o
f
J
-
1
4
7
f
o
r
c
o
n
s
u
m
e
r
s
;
t
h
e
f
i
n
i
s
h
e
d
d
r
u
g
s
u
b
s
t
a
n
c
e
e
x
i
s
t
s
o
n
l
y
w
i
t
h
i
n
i
t
s
i
n
v
e
s
t
i
g
a
t
i
o
n
a
l
-
d
r
u
g
p
r
o
g
r
a
m
.
A
n
y
t
h
i
n
g
s
o
l
d
t
o
t
h
e
p
u
b
l
i
c
i
s
r
e
s
e
a
r
c
h
-
g
r
a
d
e
p
o
w
d
e
r
o
f
v
a
r
i
a
b
l
e
p
r
o
v
e
n
a
n
c
e
.
B
u
y
e
r
s
w
h
o
a
n
a
l
y
z
e
s
u
c
h
m
a
t
e
r
i
a
l
t
y
p
i
c
a
l
l
y
r
e
l
y
o
n
a
c
e
r
t
i
f
i
c
a
t
e
o
f
a
n
a
l
y
s
i
s
,
t
h
i
r
d
-
p
a
r
t
y
i
d
e
n
t
i
t
y
c
o
n
f
i
r
m
a
t
i
o
n
(
f
o
r
e
x
a
m
p
l
e
H
P
L
C
o
r
m
a
s
s
s
p
e
c
t
r
o
m
e
t
r
y
)
,
a
n
d
p
u
r
i
t
y
f
i
g
u
r
e
s
,
b
u
t
t
h
e
s
e
d
o
c
u
m
e
n
t
s
a
r
e
s
e
l
f
-
r
e
p
o
r
t
e
d
b
y
v
e
n
d
o
r
s
a
n
d
a
r
e
n
o
t
i
n
d
e
p
e
n
d
e
n
t
l
y
v
e
r
i
f
i
a
b
l
e
.
A
b
s
e
n
c
e
o
f
a
b
a
t
c
h
-
s
p
e
c
i
f
i
c
C
O
A
,
v
a
g
u
e
s
o
u
r
c
i
n
g
,
a
n
d
"
p
r
o
p
r
i
e
t
a
r
y
"
b
l
e
n
d
s
a
r
e
r
e
d
f
l
a
g
s
.
N
o
n
e
o
f
t
h
i
s
m
a
k
e
s
t
h
e
m
a
t
e
r
i
a
l
l
a
w
f
u
l
o
r
s
a
f
e
f
o
r
h
u
m
a
n
u
s
e
.

Safer, legal alternative we recommend

NMN It To Win It. For the same cellular-aging/longevity goal, our NMN (a NAD+ precursor) is a legal supplement covering a similar mechanism.

See our recommended pick

Find J-147 →

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

Is J-147 proven to treat or prevent Alzheimer's disease?

No. The Alzheimer's evidence is from mouse and cell models. The only human study to date was an early Phase 1 safety and pharmacokinetics trial in healthy volunteers, which was not designed to measure cognitive benefit. There is no robust human evidence that J-147 treats, prevents, or slows Alzheimer's.

How is J-147 related to curcumin?

It is a synthetic derivative. Researchers started from curcumin, made an analog called CNB-001, and then optimized it further into J-147 for better potency, stability, and brain penetration. J-147 is a distinct chemical entity, not curcumin or a curcumin extract.

What is J-147's mechanism of action?

The leading proposed mechanism is partial inhibition of mitochondrial ATP synthase (ATP5A), which nudges cellular energy signaling toward the CAMKK2/AMPK/mTOR pathway. It also shows antioxidant, anti-inflammatory, and neurotrophic-factor-boosting effects in cell models. The mechanism is proposed and preclinical, not fully settled.

Is J-147 legal to buy in the US?

It is not FDA-approved and is not a legal dietary supplement. It is generally sold gray-market as a research chemical labeled not for human consumption. Selling it for human use is an unapproved new-drug violation, and the compound's identity, purity, and safety for consumers are unregulated.

What dose is used?

This is informational only and not a protocol. The frequently cited figure (around 10 mg/kg/day) is a mouse dose that does not translate directly to humans, and the Phase 1 human doses have not been established as effective or approved. There is no validated human dose. Anyone considering it should consult a physician.

Is J-147 safe?

Its safety in humans is largely unknown. One Phase 1 study looked at short-term tolerability in healthy volunteers; there is no long-term human safety data, no data in patients, and no oversight for gray-market material. Treat it as an investigational drug with unquantified risk.

References & further reading

PubMed: J147 curcumin derivative Alzheimer neuroprotective
PubMed: J147 ATP synthase ATP5A AMPK Goldberg aging
PubMed: J147 SAMP8 aged mice cognitive impairment reversal
ClinicalTrials.gov: J147 NCT03838185 single ascending dose healthy volunteers
PubMed: J147 CNB-001 curcumin derivative neurotrophic Schubert Maher